Zhejiang Heze Pharmaceutical Technology
Pharmaceutical R&D, clinical trials, and MAH services.
About Zhejiang Heze Pharmaceutical Technology
Zhejiang Heze Pharmaceutical Technology Co., Ltd. is a service-oriented platform company centered on drug research and development, also engaging in drug marketing authorization holder (MAH) certification and transfer. Established on October 27, 2006, by Ni Sheng, the company is headquartered in Hangzhou, China. Ni Sheng, who holds a bachelor's degree in pharmacy, served as a technician and project leader at the Zhejiang Provincial Institute of Traditional Chinese Medicine from 1994 to 2003 before starting his entrepreneurial journey. The company's business model is driven by both R&D services and industrial operations, offering a comprehensive suite of services that includes pharmaceutical research, clinical trials, and registration and declaration. It operates as a Contract Research Organization (CRO) and was a pioneer in implementing China's MAH system, which allows research institutions to hold drug marketing licenses. Heze Pharmaceutical obtained the first Drug Manufacturing License for a pharmaceutical R&D institution in China, enabling it to provide integrated R&D services and solutions for global MAH clients. Heze Pharmaceutical's services cover the entire pharmaceutical industry chain. Core services include generic drug development, consistency evaluation of generic drugs, innovative drug development, and clinical trial services. The firm has established various technology platforms for small molecule drugs, peptide drugs, and different drug delivery systems like oral, injection, and topical applications. It also provides Contract Development and Manufacturing Organization (CDMO) services and third-party testing for aspects like genotoxic impurities and elemental impurities. With experience in over 1,000 projects, its therapeutic areas include liver disease, gynecology, diabetes, and oncology. The company has developed a portfolio of its own products, including both innovative and generic drugs. Through its subsidiaries, such as Kunyuan Pharmaceutical and Yiyuan Pharmaceutical, it handles MAH conversion, clinical research, and other specialized services.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2026 | $0 | — | Taizhou Capital Group | ↗ |
| EARLY VC✓Equity / VC | Sep 2023 | $28M | $110M | CITIC Capital · JIC Investment · Fu Zhe Capital · Zhengzhou High-tech Fund | ↗ |
Growth signals
Latest recorded traffic for Zhejiang Heze Pharmaceutical Technology is 120 monthly website visits, down 33.3% over the last three months. Zhejiang Heze Pharmaceutical Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
GranulesIntegrated pharmaceutical manufacturing from API to dosages. |
— | Operational | 514 | — | — |
Alida PharmaceuticalsEuropean commercialization partner for specialty pharmaceutical assets. |
Spain | Operational | |||
Nivaris Pharma Private LimitedManufacturing medicinal substances for the pharmaceutical industry. |
Pune, India | Operational | |||
Apothecon PharmaceuticalsNiche APIs, peptides, and complex formulation manufacturing. |
India | Operational | |||
GalenicapPharmaceutical development focusing on value-added medicines. |
City of Brussels, Belgium | Operational | |||
ScieGen Pharmaceuticals IncGeneric solid oral dosage pharmaceutical manufacturer. |
Town of Smithtown, United States | Operational | |||
Purpose PharmaCommercializing pharmaceutical products for rare and specialty diseases. |
Stockholms kommun, Sweden | Operational | |||
Comhand VenturesBiopharmaceutical development and commercialization of proprietary APIs. |
Colombia | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhejiang Heze Pharmaceutical Technology in its local ecosystem
The Zhejiang Heze Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CITIC Capital
JIC Investment- FCFu Zhe Capital
- ZFZhengzhou High-tech Fund
Other known investors1 additional known investor
- TGTaizhou Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhejiang Heze Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhejiang Heze Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










